We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New, Highly Accurate, POC Test Measures Level of Neutralizing Antibodies (NAb) to COVID-19, Including Variants

By LabMedica International staff writers
Posted on 22 Dec 2021
Image: A prototype of the test (Photo courtesy of Burnet Institute)
Image: A prototype of the test (Photo courtesy of Burnet Institute)

A new, highly accurate, point-of-care (POC) test can measure the level of neutralizing antibodies (NAb) to COVID-19, including variants.

The test, developed by scientists at the Burnet Institute (Melbourne, Australia) and the Peter Doherty Institute for Infection and Immunity (Melbourne, Australia), provides a readout from a fingerprick of blood in less than 20 minutes. The test is the first of its type globally, and could also be useful to indicate when a vaccine booster may be required. While there are many POC tests that can measure the overall level of antibody to SARS-CoV-2, and use this to estimate neutralizing antibodies, this is the only test to measure neutralizing antibody activity, which correlates with immune protection from serious disease in COVID-19.

The emergence of the Omicron variant, which early studies suggest may be up to 40-times less sensitive to patient NAb than Delta, means that some people will go from having enough NAb to be protected, to not having enough. The test provides a new option for immunity screening to support COVID-19 vaccination and control programs, particularly in time-critical and low- and middle-income settings where laboratory-based testing is difficult or impossible for many to access.

“One of the key elements of the test is that it can work with fingerprick whole blood, which is essential if it is really going to be used at point-of-care,” said study joint supervising author, Associate Professor David Anderson, Burnet Institute Deputy Director and Chief Scientific Officer of the Burnet Diagnostics Initiative.

“We envisage that this test may be part of a set of indications that will help to determine who may need a booster vaccine,” said Dr. Tom Fulford from the Doherty Institute. “This can also be adapted so that it can provide information about whether an individual has protective antibodies against particular variants of concern.”

Related Links:
Burnet Institute 
Doherty Institute 

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Gold Member
Collection and Transport System
PurSafe Plus®

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more